AlexanderDimitriosColevasMD

Oncology • Palo Alto, CA

Head & Neck Cancer, Hematologic Oncology

Professor, Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Colevas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Colevas' full profile

Already have an account?

Office
300 Pasteur Dr
Palo Alto, CA 94304
Phone+1 650-723-4000

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1996
Johns Hopkins UniversityResidency, Internal Medicine, 1989 - 1992
Johns Hopkins University School of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 2007 - 2026
MD State Medical License 1991 - 2008
MA State Medical License 1993 - 2001
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) Start of enrollment: 2008 Dec 10
Completed
Phase 2
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Start of enrollment: 2013 Mar 01
Terminated
Phase 2
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Start of enrollment: 2017 Jul 17
Completed
Phase 2
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Start of enrollment: 2011 Oct 01
Completed
Phase 2
Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies Start of enrollment: 2022 Jan 25
Recruiting
Phase 2
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer Start of enrollment: 2019 Feb 11
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) Start of enrollment: 2019 Apr 04
Terminated
Phase 1, Phase 2
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) Start of enrollment: 2017 May 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx Start of enrollment: 1999 Aug 01
Unknown status
Phase 2
Join now to see all

Publications & Presentations

PubMed

744 citations
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Maura L. Gillison, Andy Trotti, Jonathan Harris, Avraham Eisbruch, Paul M. Harari
Lancet. 2019-01-05
2676 citations
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, Joël Guigay, A. Dimitrios Colevas
The New England Journal of Medicine. 2016-10-08
102 citations
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Robert L. Ferris, Lisa Licitra, Jérôme Fayette, Caroline Even, George R. Blumenschein
Clinical Cancer Research. 2019-09-01

Journal Articles

Identification and Validation of Novel Microenvironment-Based Immune Molecular Subgroups of Head and Neck Squamous Cell Carcinoma: Implications for Immunotherapy
J Ma, D N Hayes, A Dimitrios Colevas, N Lee, Annals of Oncology

Press Mentions

I Respect You, Cancer, but You’re Killing Both of UsAugust 24th, 2024